CLINICAL TRIALS PROFILE FOR METHOTREXATE SODIUM

All Clinical Trials for METHOTREXATE SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001863 ↗	Leflunomide to Treat Uveitis	Completed	National Eye Institute (NEI)	Phase 2	1999-03-01	This study will investigate the safety and effectiveness of the drug Leflunomide to treat uveitis-an inflammation of the eye caused by an immune system abnormality. Leflunomide suppresses immune system activity and has been shown to control autoimmune diseases, such as arthritis (joint inflammation), in animals. It has also improved symptoms in patients with rheumatoid arthritis, and the Food and Drug Administration has approved it for treating patients with this disease. Eye and joint inflammation may have similar causes, and medicines for arthritis often help patients with eye inflammation. This study will examine whether Leflunomide can help patients with uveitis. Patients with uveitis who are not responding well to steroid treatment and patients who have side effects from other medicines used to treat uveitis (such as cyclosporine, cyclophosphamide, methotrexate or azathioprine) or have refused treatment because of possible side effects of these medicines may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood test and eye examination. The eye exam includes a check of vision and eye pressure, examination of the back of the eye (retina) with an ophthalmoscope and the front of the eye with a microscope. They will also undergo a procedure called fluorescein angiography to look at the blood vessels of the eye. A dye called sodium fluorescein is injected into the bloodstream through a vein. After the dye reaches the blood vessels of the eye, photographs are taken of the retina. Study participants will be divided into two groups. One group will take 100 milligrams of Leflunomide once a day for 3 days and then 20 milligrams once a day for 6 months. The other group will take a placebo-a pill that looks like the Leflunomide pill but does not contain the medicine. All patients in both groups will also take prednisone. Patients will have follow-up examinations at weeks 1, 4, 8, 12, 16, and 24 (6 months) of the study. Each follow-up visit will include a repeat of the screening exams and an evaluation of side effects or discomfort from the medicine. Those who do well and want to continue their assigned treatment after 6 months can continue that treatment for another 6 months and will have follow-up exams at months 9 and 12.
NCT00006184 ↗	Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 2	2001-02-08	Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an incurable disease with a median survival of approximately 30 months. Allogeneic stem cell transplantation (SCT) results in a high percentage of complete remissions, but it can be associated with significant treatment-related mortality, which has been primarily attributed to conventional myeloablative transplant regimens. Recent clinical studies have shown that highly immunosuppressive yet non-myeloablative doses of fludarabine-based chemotherapy can result in alloengraftment. Even with a reduction in treatment related mortality, success with allogeneic SCT is limited by a significant risk of relapse. Donor immunization with myeloma Id in the setting of a non-myeloablative allogeneic SCT may represent a novel strategy for the treatment of multiple myeloma. Objectives: Primary Objectives: To induce cellular and humoral immunity in allogeneic stem cell donors and recipients against the unique idiotype expressed by the recipient's myeloma. To determine whether antigen-specific immunity, induced in the stem cell donor, can be passively transferred to the allogeneic SCT recipient in the setting of a non-myeloablative conditioning regimen. Secondary Objectives: To evaluate the effect of the Fludarabine-(etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide) EPOCH regimen on host T cell depletion and myeloid depletion prior to allogeneic SCT. To determine the efficacy of a novel conventional chemotherapy regimen (Fludarabine-EPOCH) in the setting multiple myeloma. To determine the treatment-related morbidity and mortality of allogeneic stem cell transplantation using a non-myeloablative conditioning regimen in multiple myeloma. To determine if the re-vaccination of allogeneic stem cell donors with the unique idiotype expressed by the recipient's myeloma will enhance cellular and humoral immunity to patient specific-idiotype prior to lymphocyte donation for the treatment of patients with recurrent or progressive disease after transplantation. Eligibility: Patients 18-75 years of age with Immunoglobulin G (IgG) or Immunoglobulin A (IgA) multiple myeloma. Patients must have achieved at least a partial remission following initial conventional chemotherapy regimen or after autologous stem cell transplantation. Consenting first degree relative matched at 6/6 or 5/6 human leukocyte antigen (HLA) antigens. Design: Phase 2 trial using a non-myeloablative conditioning regimen to reduce treatment-related toxicity. Recipient will undergo a plasmapheresis to obtain starting material for the isolation of idiotype protein. Donors would be immunized with an Id vaccine prepared from the patient. Prior to transplantation patients would receive a conventional chemotherapy regimen which contains agents active in myeloma and is T cell depleting. The allogeneic SCT would be performed with a conditioning regimen consisting of cyclophosphamide and fludarabine. The stem cell source would be blood mobilized with filgrastim. Recipients will be immunized with the Id vaccine following transplantation.
NCT00045305 ↗	Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes	Completed	National Cancer Institute (NCI)	Phase 2	2005-05-01	RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes.
NCT00045305 ↗	Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes	Completed	Eastern Cooperative Oncology Group	Phase 2	2005-05-01	RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes.
NCT00074165 ↗	Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen	Terminated	National Cancer Institute (NCI)	Phase 2	2003-01-01	RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels around the brain and allow anticancer substances to be delivered directly to the brain tumor. Chemoprotective drugs such as sodium thiosulfate may protect normal cells from the side effects of carboplatin-based chemotherapy. Combining rituximab with chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate in treating patients who have refractory or recurrent primary CNS lymphoma.

Clinical Trial Conditions for METHOTREXATE SODIUM

Condition Name

Condition Name for METHOTREXATE SODIUM
Intervention	Trials
Acute Lymphoblastic Leukemia	4
Leukemia	4
Lymphoma	3
B Acute Lymphoblastic Leukemia	3

Condition MeSH

Condition MeSH for METHOTREXATE SODIUM
Intervention	Trials
Leukemia	16
Precursor Cell Lymphoblastic Leukemia-Lymphoma	14
Leukemia, Lymphoid	13
Lymphoma	7

Clinical Trial Locations for METHOTREXATE SODIUM

Trials by Country

Trials by Country for METHOTREXATE SODIUM
Location	Trials
United States	319
Canada	29
Australia	13
Korea, Republic of	4
China	4

Trials by US State

Trials by US State for METHOTREXATE SODIUM
Location	Trials
Ohio	15
Minnesota	13
Florida	13
Illinois	12
California	12

Clinical Trial Progress for METHOTREXATE SODIUM

Clinical Trial Phase

Clinical Trial Phase for METHOTREXATE SODIUM
Clinical Trial Phase	Trials
PHASE4	3
PHASE2	2
Phase 4	2

Clinical Trial Status

Clinical Trial Status for METHOTREXATE SODIUM
Clinical Trial Phase	Trials
Completed	14
RECRUITING	8
Terminated	6

Clinical Trial Sponsors for METHOTREXATE SODIUM

Sponsor Name

Sponsor Name for METHOTREXATE SODIUM
Sponsor	Trials
National Cancer Institute (NCI)	13
Therapeutic Advances in Childhood Leukemia Consortium	5
OHSU Knight Cancer Institute	4

Sponsor Type

Sponsor Type for METHOTREXATE SODIUM
Sponsor	Trials
Other	49
NIH	16
Industry	10

METHOTREXATE SODIUM Market Analysis and Financial Projection

Last updated: April 28, 2026

Methotrexate Sodium: Clinical-Development Update, Market Analysis, and Forward Projections

What is methotrexate sodium’s current clinical development status?

Methotrexate sodium is an established, off-patent anticancer and immunomodulator with broad global use. The practical “clinical trials update” for methotrexate sodium in 2026 is not a single late-stage pipeline event, but a continuing pattern of trials focused on:

• New formulations and delivery strategies (including oral pharmacokinetics, subcutaneous schedules, and regimen optimization)
• New indications and line-of-therapy positioning across oncology and inflammatory disease
• Comparative effectiveness and safety in real-world or pragmatic trial designs
• Combination regimens using methotrexate backbone dosing with disease-specific agents

Because methotrexate sodium is already widely marketed in multiple dosage forms, most current clinical work tends to be incremental and regimen- or formulation-specific rather than discovery-stage development. Sponsors commonly test endpoints that reflect real-world treatment goals: reduced toxicity, maintained efficacy, or improved adherence.

For decision-making, the market-relevant point is this: there is no single, widely recognized methotrexate sodium “blockbuster” late-stage development cycle that would materially reset the global market via first approval of a new active ingredient. Instead, trial activity impacts share through:

• Brand-to-generic conversion dynamics
• Formulation switching (injectables vs oral; once-weekly regimens and supportive care protocols)
• Regional tendering and reimbursement rules that favor specific presentations

Which trial signals matter most for commercial outlook?

Commercially meaningful trial signals for methotrexate sodium tend to cluster into four buckets:

1) Formulation and administration optimization

Trials that compare:

• Oral versus subcutaneous administration
• Dose escalation or split dosing schedules
• Supportive regimens (folate supplementation schedules, rescue strategies for toxicity)

These studies can shift utilization toward specific presentations even when the active ingredient stays constant.

2) Safety and tolerability outcomes

Methotrexate safety work is consistently focused on:

• Hepatotoxicity monitoring and mitigation
• Myelosuppression risk stratification
• Drug interaction patterns (notably concomitant anti-inflammatories and other immunosuppressants)
• Renal function adjustments for dosing continuity

3) Combination regimens

Methotrexate often anchors combinations in:

• Oncology protocols where it is a standard cytotoxic component
• Immunology and rheumatology where it is paired with biologics or targeted synthetic therapies

4) Pragmatic and comparative trials

Where these trials are registered, they tend to influence:

• Treatment guidelines
• Payor protocols
• Physician preferences for regimen standardization

What is the global market structure for methotrexate sodium?

Methotrexate sodium is sold globally in multiple dosage forms and strengths. The market structure is defined by:

• Extensive generic competition
• Multiple manufacturers across geographies
• Ongoing demand due to standard-of-care positioning in oncology and inflammatory disease

Market category split (high-level)

Methotrexate sodium demand concentrates in:

• Rheumatology (rheumatoid arthritis and related inflammatory conditions)
• Dermatology (psoriasis and related conditions)
• Oncology (various regimens where methotrexate is part of standard chemotherapy or maintenance)

Competitive landscape

The competitive set is dominated by:

• Generic manufacturers
• Reference-brand legacy products in certain markets
• Formulation-specific differentiation (injectables, oral solutions/tablets, and patient-support packaging)

This structure implies that pricing is primarily driven by tendering, reimbursement, and national generic policies, not by clinical differentiation at the active ingredient level.

How big is the methotrexate sodium market, and where does growth come from?

A precise “single number” global market value depends on how analysts define the drug (methotrexate base vs salts, oral vs injectables, oncology vs autoimmune segmentation, and whether data is aggregated under methotrexate broadly or methotrexate sodium specifically). Without a consistent dataset definition in this response, the actionable forecast is best expressed through drivers and directional trends:

Demand drivers

• Persistent guideline use in rheumatology and oncology regimens
• Long treatment duration in chronic inflammatory diseases
• Multiple-line utilization in oncology protocols
• Availability and affordability via generics, sustaining baseline consumption

Growth drivers

• Patient persistence and regimen optimization supported by safety monitoring and clinical practice improvements
• Switching to subcutaneous administration in appropriate patients when oral tolerability is limited
• Expanded combination protocols that keep methotrexate in the backbone when biologics or targeted agents are introduced

Headwinds

• Price pressure from generics
• Tight pharmacy formularies and tendering, which compress net pricing
• Potential substitution by alternative disease-modifying agents in rheumatology, depending on local reimbursement and patient response

What is the 2026-2031 projection for methotrexate sodium?

Given the off-patent status and generic competition, methotrexate sodium market growth usually follows a pattern of:

• Low to mid single-digit volume growth (driven by disease prevalence, persistence, and incremental regimen shifts)
• Flat to declining real price (driven by generic substitution and tender pressure)
• Near-term stability with periodic step changes from tender cycles and formulation preferences

Projection framework (directional, business-useful)

Base case (most likely):

• Revenue CAGR stays modest because volume increases are offset by price compression.
• Market share shifts across manufacturers occur through tenders and contract wins rather than a new clinical breakthrough.

Upside case:

• Faster adoption of preferred formulations (notably subcutaneous where clinically appropriate)
• Broader use in combination regimens that retain methotrexate as a backbone
• Healthcare system catch-up in under-treated populations

Downside case:

• Intensifying substitution toward higher-priced targeted therapies where reimbursement relaxes
• Aggressive tendering that drives further net price erosion
• Safety monitoring constraints in resource-limited settings that reduce achievable dosing continuity

What are the current commercial implications by product type?

Even with a single active ingredient, commercial outcomes vary by presentation.

Oral solid and solution forms

• Most exposed to rapid generic price competition
• Likely to hold volume if dosing simplicity aligns with guideline recommendations

Subcutaneous injectables

• Often face slightly better defensibility due to administration training and tolerability-driven switching
• Can gain share in patients needing tolerability improvement or adherence support

Pack size and patient-support formats

• In tendered markets, packaging and procurement convenience matter
• Some share gains occur without clinical superiority through contract packaging and supply reliability

Which sources define the standard-of-care role of methotrexate sodium?

Methotrexate is widely documented as a cornerstone therapy and is incorporated into clinical practice guidance across rheumatology and oncology pathways. The key point for market projection is that guidelines sustain baseline demand even as competitive pricing pressures increase.

Clinical labeling and standardized monographs confirm:

• Methotrexate is used in oncology regimens and in inflammatory diseases.
• Safety monitoring requirements and contraindication frameworks remain central to dosing continuity. (See prescribing and safety information referenced below.) [1]

What is the risk-adjusted outlook for investors and R&D partners?

For investment or partnerships, the methotrexate sodium landscape favors strategies that monetize operational or lifecycle advantages:

1) Supply and contracting execution

• Tender wins drive revenue more than clinical differentiation.
• Manufacturing reliability and distribution performance affect share.

2) Formulation lifecycle management

• Superior usability (injection devices, dosing instructions, patient support) can improve switching even in generics.
• Quality consistency supports procurement confidence.

3) Regimen-level evidence and guideline uptake

• Trials that translate into guideline language can influence utilization pathways.
• However, this does not usually create patent-protected revenue unless coupled to a protected formulation, device, or method claims.

4) Pharmacovigilance and risk mitigation

• Safety monitoring adherence affects patient persistence.
• Lower discontinuation through better monitoring protocols improves realized volume.

Key Takeaways

• Methotrexate sodium’s “clinical update” is dominated by incremental formulation and regimen optimization, not a new late-stage active-ingredient approval cycle.
• Market growth is expected to be modest and volume-led, with price compression typical of off-patent generics.
• Commercial differentiation typically comes from presentation (oral vs subcutaneous), contracting execution, and supply reliability, rather than new clinical breakthroughs.
• The 2026-2031 outlook most likely reflects stable demand with low revenue CAGR, driven by persistence in chronic inflammatory diseases and continued use in oncology regimens.
• Investor and R&D value creation centers on lifecycle strategies (formulation and device usability, evidence translation into practice, and supply execution).

---

FAQs

1) Is methotrexate sodium still actively studied in clinical trials?

Yes, studies continue, primarily focused on regimen optimization, safety monitoring, and formulation or delivery comparisons rather than new foundational efficacy signals.

2) What drives methotrexate sodium market revenue most: volume or price?

Price is the bigger swing factor because generic competition compresses net pricing; revenue typically tracks volume first, with price acting as a headwind.

3) Do clinical trial results for methotrexate sodium create patent-protected value?

Often not at the active ingredient level. Value usually accrues through formulation-specific, device, or method-of-use differentiation where supported by protectable claims and local regulatory pathways.

4) Which indications matter most commercially?

Rheumatology and dermatology chronic inflammatory use support steady baseline demand; oncology contributes additional utilization through multi-regimen usage.

5) What is the most important factor for market share in generics?

Tendering, procurement contracts, and supply continuity typically dominate over marginal clinical differences.

---

References

[1] National Library of Medicine. (n.d.). Methotrexate: Drug information and prescribing references. U.S. National Library of Medicine. https://www.nlm.nih.gov/